NY-ESO-1 (CTAG1B) expression in mesenchymal tumors

Makoto Endo, Marieke A. De Graaff, Davis R. Ingram, Simin Lim, Dina C. Lev, Inge H. Briaire-De Bruijn, Neeta Somaiah, Judith V.M.G. Bovée, Alexander J. Lazar, Torsten O. Nielsen

研究成果: ジャーナルへの寄稿記事

32 引用 (Scopus)

抄録

New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90% of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1.

元の言語英語
ページ(範囲)587-595
ページ数9
ジャーナルModern Pathology
28
発行部数4
DOI
出版物ステータス出版済み - 4 8 2015

Fingerprint

Myxoid Liposarcoma
Synovial Sarcoma
Chondrosarcoma
Neoplasms
Testicular Neoplasms
Immunotherapy
Monoclonal Antibodies
Staining and Labeling
Antigens

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

これを引用

Endo, M., De Graaff, M. A., Ingram, D. R., Lim, S., Lev, D. C., Briaire-De Bruijn, I. H., ... Nielsen, T. O. (2015). NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Modern Pathology, 28(4), 587-595. https://doi.org/10.1038/modpathol.2014.155

NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. / Endo, Makoto; De Graaff, Marieke A.; Ingram, Davis R.; Lim, Simin; Lev, Dina C.; Briaire-De Bruijn, Inge H.; Somaiah, Neeta; Bovée, Judith V.M.G.; Lazar, Alexander J.; Nielsen, Torsten O.

:: Modern Pathology, 巻 28, 番号 4, 08.04.2015, p. 587-595.

研究成果: ジャーナルへの寄稿記事

Endo, M, De Graaff, MA, Ingram, DR, Lim, S, Lev, DC, Briaire-De Bruijn, IH, Somaiah, N, Bovée, JVMG, Lazar, AJ & Nielsen, TO 2015, 'NY-ESO-1 (CTAG1B) expression in mesenchymal tumors', Modern Pathology, 巻. 28, 番号 4, pp. 587-595. https://doi.org/10.1038/modpathol.2014.155
Endo M, De Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-De Bruijn IH その他. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Modern Pathology. 2015 4 8;28(4):587-595. https://doi.org/10.1038/modpathol.2014.155
Endo, Makoto ; De Graaff, Marieke A. ; Ingram, Davis R. ; Lim, Simin ; Lev, Dina C. ; Briaire-De Bruijn, Inge H. ; Somaiah, Neeta ; Bovée, Judith V.M.G. ; Lazar, Alexander J. ; Nielsen, Torsten O. / NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. :: Modern Pathology. 2015 ; 巻 28, 番号 4. pp. 587-595.
@article{f0aad8b84a1f4449aa72b9ceccf1e5e1,
title = "NY-ESO-1 (CTAG1B) expression in mesenchymal tumors",
abstract = "New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88{\%}), followed by synovial sarcomas (49{\%}), myxofibrosarcomas (35{\%}), and conventional chondrosarcomas (28{\%}). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90{\%} of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1.",
author = "Makoto Endo and {De Graaff}, {Marieke A.} and Ingram, {Davis R.} and Simin Lim and Lev, {Dina C.} and {Briaire-De Bruijn}, {Inge H.} and Neeta Somaiah and Bov{\'e}e, {Judith V.M.G.} and Lazar, {Alexander J.} and Nielsen, {Torsten O.}",
year = "2015",
month = "4",
day = "8",
doi = "10.1038/modpathol.2014.155",
language = "English",
volume = "28",
pages = "587--595",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - NY-ESO-1 (CTAG1B) expression in mesenchymal tumors

AU - Endo, Makoto

AU - De Graaff, Marieke A.

AU - Ingram, Davis R.

AU - Lim, Simin

AU - Lev, Dina C.

AU - Briaire-De Bruijn, Inge H.

AU - Somaiah, Neeta

AU - Bovée, Judith V.M.G.

AU - Lazar, Alexander J.

AU - Nielsen, Torsten O.

PY - 2015/4/8

Y1 - 2015/4/8

N2 - New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90% of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1.

AB - New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90% of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1.

UR - http://www.scopus.com/inward/record.url?scp=84926520805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926520805&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2014.155

DO - 10.1038/modpathol.2014.155

M3 - Article

C2 - 25412843

AN - SCOPUS:84926520805

VL - 28

SP - 587

EP - 595

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 4

ER -